Giuseppe Procopio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses follow-up results from the randomized Phase II RESORT trial (NCT01444807) investigating the efficacy of radical metastasectomy followed by sorafenib versus observation in patients with metastatic renal cell carcinoma (mRCC). The study analyzed data from 68 patients with mRCC, 32 of whom received sorafenib therapy after radical metastasectomy. Recurrence-free survival (RFS) was the primary endpoint of the trial. The trial found that sorafenib after radical metastasectomy in patients with mRCC did not prolong RFS in comparison to observation. This interview took place during the 2021 Genitourinary Cancers Symposium.
Dr Giuseppe Procopio, MD, has participated in an advisory role for AstraZeneca, Bayer, Ipsen, Janssen, Merckx, MSD Pharmaceuticals, Novartis, Pfizer and BMS.